Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study

Marta Vasylyev, Ferdinand W.N.M. Wit, Carlijn C.E. Jordans, Robin Soetekouw, Steven F.L. van Lelyveld, Gert Jan Kootstra, Corine E. Delsing, Heidi S.M. Ammerlaan, Marjo E.E. van Kasteren, Annemarie E. Brouwer, Eliane M.S. Leyten, Mark A.A. Claassen, Robert Jan Hassing, Jan G. den Hollander, Marcel van den Berge, Anna H.E. Roukens, Wouter F.W. Bierman, Paul H.P. Groeneveld, Selwyn H. Lowe, Berend J. van WelzenOlivier Richel, Jeannine F. Nellen, Guido E.L. van den Berk, Marc van der Valk, Bart J.A. Rijnders, Casper Rokx^*, AIDS Therapy Evaluation in the Netherlands (ATHENA) Observational HIV CohortShow 7 moreShow less